REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > > Cyclopentanohydrophenanthrene Ring System Cyclopentanohydrophenanthrene Ring SystemCyclopentanohydrophenanthrene Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021358 - Localized delivery of cardiac inotropic agents The present invention provides novel methods for the localized delivery of inotropic agents to the heart, including specific regions of the heart, such as the ventricles, for example in a subject undergoing cardiothoracic surgery, with the aim of supporting the myocardial contractile function of the heart. ... 01/11/07 - 20070010462 - Core 2 glcnac-t inhibitors iii R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties, and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof. ... 01/11/07 - 20070010461 - Core 2 glcnac-t inhibitors S1 and S2 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester thereof. ... 01/11/07 - 20070010460 - Multiple sclerosis therapy and diagnosis A method of treatment of Multiple Sclerosis in a subject is disclosed comprising administering to the subject a compound capable of reducing the activity of Core 2 GlcNAc-T. Also disclosed is a method of diagnosing Multiple Sclerosis in a subject and a method of determining the utility of a test ... 01/11/07 - 20070010459 - Application of asiatic acid and its derivatives to treat pulmonary fibrosis Compositions comprising asiatic acid and its derivatives and asiaticoside and the methods of use there of to treat pulmonary fibrosis are provided. ... 12/28/06 - 20060293255 - Method for regulating nutrient absorption with ginsenosides There is provided a method for regulating the absorption of a nutrient in a subject, including administering to the subject an effective amount of a ginsenoside compound purified from Panax notoginseng for modulating transportation of the nutrient across gut cells of the subject. ... 12/07/06 - 20060276415 - 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed ... 12/07/06 - 20060276414 - Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain The present invention relates to a method of treating or preventing musculoskeletal pain in a mammal receiving administration of an estrogen. suppressant selected from the group consisting of aromatase inhibitors, GnRH analogues, cyclo-oxy-genase 2 (COX-2) inhibitors, 17β-hydroxysteroid dehydrogenase type 1 inhibitors, progestogens, anti-estrogens and combinations thereof, said method comprising the ... 11/09/06 - 20060252705 - Sterol glucoside toxins The invention relates to the identification of sterol glucoside toxins, and provides methods for detecting and detoxifying the compounds, as well as therapeutic methods for treating subjects exposed to such toxins. In alternative embodiments, the toxins may for example include beta-sitostrol-beta-D-glucoside (5-cholesten-24b-ethyl-3b-ol-D-glucoside) or cholesterol glucoside (5-cholesten-3b-ol-3b-D-glucoside). ... 11/09/06 - 20060252704 - Polymorphs of 3-o-(3',3'-dimethylsuccinyl)betulinic acid di-n-methyl-d-glucamine The present invention relates to crystalline polymorphs of 3-O-(3′,3′-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine salt (“DSB•2NMG)”), pharmaceutical compositions of the same and use of the same as an active pharmaceutical agent in the treatment of HIV related disorders. ... 11/02/06 - 20060247182 - Cyclooxygenase-2 inhibitory withanolide compositions and method Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1. ... 10/19/06 - 20060234956 - Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof The present invention relates to a series of dicarboxylic acid ester derivatives of ginsenosides such as succinate and glutarate derivatives of 20-O-β-D-glucopyranosyl-protopanaxadiol (compound K, abbreviated as CK), preparation thereof and pharmaceutical uses thereof. The dicarboxylic acid ester derivatives of ginsenosides of the present invention can be used to form pharmaceutical ... 10/19/06 - 20060234955 - Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders A method of inhibiting the secretion of IL-8 and other pro-inflammatory cytokines from cells secreting elevated levels of these compounds is provided. The method includes contacting the cell with a composition comprising a cardiac glycoside such as oleandrin. The cardiac glycoside can be used to treat cystic fibrosis and other ... 09/28/06 - 20060217324 - Rnai modulation of the nogo-l or nogo-r gene and uses thereof The invention relates to compositions and methods for modulating the expression of Nogo-L or Nogo-R genes, and more particularly to the downregulation of Nogo-L or Nogo-R by chemically modified oligonucleotides. ... 09/14/06 - 20060205679 - Topical and oral formulations of cardiac glycosides for treating skin diseases The present invention provides method, preparation and use of a variety of pharmaceutical compositions containing at least one digitalis glycoside such as oleandrin, odoroside-A, neriifolin, proscillaridin-A, methyl-proscillaridin-A, digitoxin, digoxin alone or at least one digitalis glycoside complexed with cyclodextrins. In another aspect, the present invention provides an effective method to ... 08/24/06 - 20060189550 - Immunostimulatory, covalently lipidated oligonucleotides Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and/or non-immunological agents. Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer ... 08/17/06 - 20060183696 - Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract wherein M represents a macrolide subunit possessing the property of accumulation in inflammatory cells, T represents an anti-inflammatory subunit that can be a steroid or nonsteroid (nonsteroidal moiety) derived from a non-steroid drug with anti-inflammatory, analgesic and/or antipyretic activity (NSAID) and L represents a linker covalently linking M and T. ... 07/27/06 - 20060166903 - Phosphocholine linked prodrug derivatives Disclosed are compounds of general formula (I) that function as prodrugs, thereby increasing bioavailabilities of the linked therapeutic agents, wherein the LINKER is (i) substituted or unsubstituted alkyl, (ii) substituted or unsubstituted alkenyl, (iii) substituted or unsubstituted alkanoyl, (iv) substituted or unsubstituted alkenoyl wherein the double bond is cis, and ... 07/20/06 - 20060160752 - Promoter for the production of hyaluronic acid containing ginsenoside compound k There are provided a promoter containing ginsenoside compound K for the production of hyaluronic acid, and more particularly, a new efficacy of 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (compound K), a chief metabolite of ginseng saponin, to increase the expression of hyaluronic acid synthase gene in human cell and thereby to promote the production of ... 07/06/06 - 20060148725 - Selective 11beta hsd inhibitors and methods of use thereof Methods for treating glucocorticoid associated states using selective 11β-HSD1-dehydrogenase, 11β-HSD1-reductase and 11β-HSD2 dehydrogenase modulating compounds are described. ... 06/22/06 - 20060135443 - Use of na*/k*-atpase inhibitors and antagonists thereof The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating hypoxia-related pathological conditions, such as Alzheimer's Disease, and those involving excessive angiogenesis, especially those non-cancer pathological conditions. The invention provides the use of Na+/K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), ... 06/22/06 - 20060135442 - Pancreatic cancer treatment using na+/k+ atpase inhibitors The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating pancreatic cancers. The invention provides the use of Na+/K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents (chemo- or radio-therapies, etc.) for ... 06/22/06 - 20060135441 - Combinatorial chemotherapy treatment using na+/k+ atpase inhibitors The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.), including stimulation of the hypoxic stress response in tumor cells. ... 06/15/06 - 20060128639 - Regulators of the hedgehog pathway, compositions and uses related thereto The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations. ... 05/25/06 - 20060111306 - Dehydroephiandrosterone and ubiquinone compositions for treating asthma and bronoconstriction A composition and various formulations comprise preventative or therapeutic amounts of an epiandrosterone, analogue thereof or salt thereof, and/or a ubiquinone or salt thereof, and a pharmaceutically or veterinarily acceptable carrier or diluent. The composition and formulations are useful for treating bronchoconstriction, respiratory tract inflammation and allergies, asthma, and cancer. ... 05/04/06 - 20060094668 - Coadministration of tigecycline and digoxin The invention pertains to treatment of bacterial infections with tigecycline and cardiac insufficiency with digoxin by coadministration to a human in need thereof. ... 03/30/06 - 20060069044 - Modified glycosaminoglycans, pharmaceutical compositions and methods for oral delivery thereof This invention provides a composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid. This invention also provides a pharmaceutical composition comprising a depolymerized glycosaminoglycan or derivative thereof covalently linked to a bile acid and a pharmaceutically acceptable carrier. Finally, this invention provides a method for ... 03/30/06 - 20060069043 - Chiral separation, characterization and biological action of optically active isomers of digoxin Disclosed herein is the method for separation of enantiomers or isomers of digoxin. These isomers are to be used in the treatment of heart failure without adverse or unneeded cardiac actions in humans. Additionally what is claimed is an isolate with less or no cardiac contractile effect but with AV ... 03/23/06 - 20060063723 - Pharmaceutical composition comprising esterol derivatives for use in cancer therapy The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints. ... 02/16/06 - 20060035845 - Use of immune cell specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract wherein M represents a macrolide subunit possessing the property of accumulation in inflammatory cells, T represents an anti-inflammatory subunit that can be a steroid or nonsteroid (nonsteroidal moiety) derived from a non-steroid drug with anti-inflammatory, analgesic and/or antipyretic activity (NSAID) and L represents a linker covalently linking M and T. ... 01/26/06 - 20060019907 - Guggulsterone: an inhibitor of nuclear factor - kappab and ikappabalpha kinase activation and uses thereof The present invention provides an inhibitor of NF-κB, guggulsterone and its analogs. Guggulsterone suppresses NF-κB activation induced by TNF, phorbol ester, okadaic acid, cigarette smoke, H2O2 and IL-1β, as well as constitutive NF-κB activation expressed in most tumor cells. One mechanism by which guggulsterone inhibits activation of NF-κB is through ... 01/19/06 - 20060014704 - Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production The present invention provides novel ginsenoside compounds, compositions (e.g. pharmaceutical compositions) comprising the ginsenoside compounds, and methods for the synthesis of these ginsenoside compounds. Additionally, the present invention provides methods for inhibiting beta-amyloid peptide production and methods for treating or preventing a pathological condition, particularly, neurodegeneration diseases (e.g. Alzheimer's disease), ... 01/05/06 - 20060003947 - Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols The present invention is directed to soft gel compositions, methods of delivery and packaged nutraceuticals of the soft gel compositions that include at least one polymethoxylated flavone and, optionally, at least one tocotrienol. Optional active ingredients include a phytosterol, DHA, EPA, coenzyme Q-10 or an analog thereof and mixtures thereof. ... 12/01/05 - 20050267051 - Antineoplastic and anti-hiv conjugates of steroid acid and nucleosides A conjugate comprising a nucleoside ester of a steroid acid, said steroid acid having a cyclopentanophenanthrene carbon-carbon skeleton or a homolog thereof and containing up to a maximum of 40 carbon atoms and having at least one carboxylic group covalently bonded thereto, said ester exhibiting at least one activity selected ... 12/01/05 - 20050267050 - Compositions and methods for treating mdma-induced toxicity This invention relates to methods and compositions for treating or preventing the symptoms associated with toxicity induced by ingestion of MDMA. In one aspect, the present invention is related to methods for treating or preventing the symptoms associated with MDMA, or MDMA-related psychoactive drugs by administering to a subject in ... 11/24/05 - 20050261209 - Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance ... 11/10/05 - 20050250709 - Anti-neoplastic agents, combination therapies and related methods In certain aspects, the invention relates to the discovery of novel compositions for use in the treatment of a neoplastic disorder. Further aspects of the invention relate to the discovery that cell signaling may be exploited to identify significant genes in cancer cell lines and to generate reporter gene systems ... 11/03/05 - 20050245465 - Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptitde production The present invention provides compositions and methods for treating and preventing Alzheimer's disease by administering to a subject an effective amount of a dammarane or ginsenoside compound. The invention also provides compositions and methods for modulating beta-amyloid protein production, including Aβ42 in a cell. The invention further provides compositions and ... 10/27/05 - 20050239719 - Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension Methods of treating, preventing and managing pulmonary hypertension are disclosed. Specific methods encompass the administration of thalidomide, or a pharmaceutically acceptable salt, solvate (e.g., hydrate), stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, surgery and/or lung transplantation. Specific second active agents are capable of ... 10/27/05 - 20050239718 - Use of hederagenin 3-o-alpha-l-rhamnopyranosyl((1-2)-[betha-d-glucopyranosyl(1-4)]-alpha-l-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors This invention relates to a use of hederagenin 3-O-α-L-rhamnopyranosyl((1→2)-[β-D-glucopyranosyl(1→4)]-α-L-arabinopyranoside or a Pulsatillae radix extract containing the same as a therapeutic agent for solid tumors. Also, this invention relates to a method of preparing a therapeutic agent for solid tumors by using hederagenin 3-0-α-L-rhamnopyranosyl(1→2)-[β-D-glucopyranosyl(1→4)]-α-L-arabinopyranoside, or a method of treating a subject ... 10/20/05 - 20050233984 - Composition for preventing or treating degenerative brain diseases comprising a hydrolysate of ginsenosides A pharmaceutical composition for preventing or treating a degenerative brain disease comprising a compound of formula I or a or a pharmaceutically acceptable salt thereof as an active ingredient: (I) wherein, R1 is H or Glc-Glc-; R2 is H or OH; R3 is H, glucose, Ara(p)-Glc- or Ara(f)-Glc-; Glc is ... 10/13/05 - 20050227928 - Glycoalkaloid compositions and various uses thereof wherein the compound includes at least one R4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other ... 10/13/05 - 20050227927 - Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a glucocorticosteroid for the treatment of asthma, chronic obstructive pulmonary disease, allergic rhinitis, or any other respiratory disease. The composition is provided in various ... 10/06/05 - 20050222049 - Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a glucocorticosteroid for the treatment of asthma, chronic obstructive pulmonary disease, allergic rhinitis, or any other respiratory disease. The composition is provided in various ... 09/22/05 - 20050209169 - Use of boswellic acid and its derivatives for inhibiting normal and increased leucocytic elastase or plasmin activity The invention concerns the use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preventing and/or combatting diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of: ... 09/22/05 - 20050209168 - Isolation of tigogenin pentaglycoside from chlorophytum nimonii The present invention provides a novel saponin tigogenin penta glycoside isolated from the aerial parts of Chlorophytum nimonii and a process for the isolation thereof as well as its use in anti-hyperglycemic and hypolipidemic activities. ... 07/21/05 - 20050159367 - Treatment of dna viral infections The synergistic combination of a loop diuretic and a cardiac glycoside is useful in the treatment of DNA viral infections. ... 07/21/05 - 20050159366 - Pharmaceutical compositions and treatment methods - 8 The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of ... 06/16/05 - 20050130911 - Nucleic acid-lipophilic conjugates The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic acid. ... 06/09/05 - 20050124560 - Crosslinkable biological material and medical uses A method for promoting angiogenesis in a patient comprising providing crosslinkable biological solution to the target tissue, wherein the crosslinkable biological solution is loaded with at least one angiogenic agent. In one embodiment, the at least one angiogenic agent is a non-protein factor selected from a group consisting of ginsenoside ... ### FreshPatents.com Support |